New Data Shows Accuracy of Vektor Medical’s AI-Powered vMap Algorithm

Vektor Medical is sharing new data showing the significant capabilities of vMap, its artificial intelligence (AI)-powered solution for enhancing cardiac arrhythmia treatment. The data highlights vMap’s 91.1% accuracy rate in differentiating epicardial from endocardial ventricular tachycardia, outperforming traditional visual echocardiogram (ECG) analysis, which achieved 62.5% accuracy.

An abstract titled, “Artificial Intelligence ECG Analysis More Accurately Identifies Epicardial versus Endocardial Ventricular Tachycardia and Pacing Compared with Visual Criteria,” presents results of a study evaluating vMap’s effectiveness in pinpointing arrhythmia sources across the left ventricle (LV) compared to visual assessment. As the only U.S. Food and Drug Administration (FDA)-cleared, non-invasive AI-based arrhythmia mapping tool, vMap empowers cardiologists with a precise, efficient method for localizing arrhythmia sources.

Researchers analyzed 136 arrhythmia or pacing episodes from 72 patients, split evenly between epicardial and endocardial sources. The vMap algorithm demonstrated 91.1% accuracy and 97.1% sensitivity, outmatching the top-performing visual ECG methods.

“vMap is an important advancement in arrhythmia care,” said Dr. Venkat Tholakanahalli, chief of Electrophysiology at the Minneapolis VA Health Care System. “With its ability to accurately localize arrhythmia sources, vMap enables us to address complex cases more effectively, ultimately contributing to improved patient outcomes. As the prevalence of arrhythmias continues to rise, tools like vMap are invaluable for helping streamline procedures and optimize our clinical time. This data underscores the transformative potential of AI in cardiac care and highlights the significant impact of Vektor Medical’s innovation on daily practice.”

Using a 12-lead ECG, vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation and ventricular tachycardia. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. A growing body of clinical evidence demonstrates vMap’s potential to not only improve patient outcomes but also reduce procedure time, optimizing workflow across the entire arrhythmia care pathway.

Headquartered in San Diego, Vektor Medical aims to revolutionize arrhythmia care for those affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company is striving to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.